Charlson FJ, Ferrari AJ, Santomauro DF, Diminic S, Stockings E, Scott JG, et al. Global epidemiology and burden of schizophrenia: findings from the global burden of disease study 2016. Schizophr Bull. 2018;44(6):1195–203.
Article PubMed PubMed Central Google Scholar
Dykxhoorn J, Kirkbride JB. The epidemiological burden of major psychiatric disorders. Oxford Textbook Pub Mental Health. 2018.
Organization WH. Depressive disorder (depression). 2023.
World Health O. Schizophrenia. World Health Organization. 2022.
World Health O. Bipolar disorder. World Health Organization. 2024.
Rush AJ. The varied clinical presentations of major depressive disorder. J Clin Psychiatry. 2007;68(Suppl 8):4–10.
Patel KR, Cherian J, Gohil K, Atkinson D. Schizophrenia: overview and treatment options. P T Peer-Rev J Form Manag. 2014;39(9):638–45.
Essau CA, Sasagawa S. Parental psychopathology and parenting style attachment as risk factors of depression. Risk Factor Depression. 2008:343–61.
Miklowitz DJ, Johnson SL. Social and familial factors in the course of bipolar disorder: basic processes and relevant interventions. Clin Psychol Sci Prac. 2009;16(2):281.
Lukoff D, Snyder K, Ventura J, Nuechterlein KH. Life events, familial stress, and coping in the developmental course of schizophrenia. Schizophr Bull. 1984;10(2):258–92.
Uher R. The changing understanding of the genetic and environmental causes of mental illness. Can J Psychiatry. 2013;58:67–8.
Price JL, Drevets WC. Neural circuits underlying the pathophysiology of mood disorders. Trends Cogn Sci. 2012;16(1):61–71.
Devor A, Andreassen OA, Wang Y, Mäki-Marttunen T, Smeland OB, Fan CC, et al. Genetic evidence for role of integration of fast and slow neurotransmission in schizophrenia. Mol Psychiatry. 2017;22(6):792–801.
Article PubMed PubMed Central Google Scholar
Chang M, Womer FY, Edmiston EK, Bai C, Zhou Q, Jiang X, et al. Neurobiological commonalities and distinctions among three major psychiatric diagnostic categories: a structural MRI study. Schizophr Bull. 2018;44(1):65–74.
Rafeyan R, Papakostas GI, Jackson WC, Trivedi MH. Inadequate response to treatment in major depressive disorder: augmentation and adjunctive strategies. J Clin Psychiatry. 2020;81(3): 27570.
Meltzer HY. Treatment-resistant schizophrenia—the role of clozapine. Curr Med Res Opin. 1997;14(1):1–20.
Maes M, Meltzer HY, Bosmans E. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr Scand. 1994;89(5):346–51.
Maes M. Evidence for an immune response in major depression: a review and hypothesis. Prog Neuropsychopharmacol Biol Psychiatry. 1995;19(1):11–38.
Maes M, Smith R. Immune activation and major depression: a hypothesis. Psychiatry Curr Med Lit Psychiatry R Soc Med. 1997;9:3–6.
Maes M, Berk M, Goehler L, Song C, Anderson G, Gałecki P, et al. Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways. BMC Med. 2012;29(10):66.
Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009;71(2):171–86.
Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67(5):446–57.
Modabbernia A, Taslimi S, Brietzke E, Ashrafi M. Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies. Biol Psychiatry. 2013;74(1):15–25.
Haapakoski R, Mathieu J, Ebmeier KP, Alenius H, Kivimäki M. Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder. Brain Behav Immun. 2015;49:206–15.
Article PubMed PubMed Central Google Scholar
Goldsmith D, Rapaport M, Miller B. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry. 2016;21(12):1696–709.
Article PubMed PubMed Central Google Scholar
Sayana P, Colpo GD, Simões LR, Giridharan VV, Teixeira AL, Quevedo J, et al. A systematic review of evidence for the role of inflammatory biomarkers in bipolar patients. J Psychiatr Res. 2017;92:160–82.
Bora E. Peripheral inflammatory and neurotrophic biomarkers of cognitive impairment in schizophrenia: a meta-analysis. Psychol Med. 2019;49(12):1971–9.
Osimo EF, Pillinger T, Rodriguez IM, Khandaker GM, Pariante CM, Howes OD. Inflammatory markers in depression: a meta-analysis of mean differences and variability in 5,166 patients and 5,083 controls. Brain Behav Immun. 2020;87:901–9.
Article PubMed PubMed Central Google Scholar
Dunleavy C, Elsworthy RJ, Upthegrove R, Wood SJ, Aldred S. Inflammation in first-episode psychosis: the contribution of inflammatory biomarkers to the emergence of negative symptoms, a systematic review and meta-analysis. Acta Psychiatr Scand. 2022;146(1):6–20.
Article PubMed PubMed Central Google Scholar
Vega-Núñez A, Gómez-Sánchez-Lafuente C, Mayoral-Cleries F, Bordallo A, Rodríguez de Fonseca F, Suárez J, et al. Clinical value of inflammatory and neurotrophic biomarkers in bipolar disorder: a systematic review and meta-analysis. Biomedicines. 2022.
Patlola SR, Donohoe G, McKernan DP. The relationship between inflammatory biomarkers and cognitive dysfunction in patients with schizophrenia: a systematic review and meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2023;121: 110668.
Berk M, Williams LJ, Jacka FN, O’Neil A, Pasco JA, Moylan S, et al. So depression is an inflammatory disease, but where does the inflammation come from? BMC Med. 2013;12(11):200.
Maes M, Carvalho AF. The compensatory immune-regulatory reflex system (CIRS) in depression and bipolar disorder. Mol Neurobiol. 2018;55(12):8885–903.
Maes M, Kubera M, Obuchowiczwa E, Goehler L, Brzeszcz J. Depression’s multiple comorbidities explained by (neuro) inflammatory and oxidative & nitrosative stress pathways. Neuroendocrinol Lett. 2011;32(1):7–24.
Koo JW, Russo SJ, Ferguson D, Nestler EJ, Duman RS. Nuclear factor-κB is a critical mediator of stress-impaired neurogenesis and depressive behavior. Proc Nat Acad Sci. 2010;107(6):2669–74.
Article PubMed PubMed Central Google Scholar
Goshen I, Kreisel T, Ben-Menachem-Zidon O, Licht T, Weidenfeld J, Ben-Hur T, et al. Brain interleukin-1 mediates chronic stress-induced depression in mice via adrenocortical activation and hippocampal neurogenesis suppression. Mol Psychiatry. 2008;13(7):717–28.
Koo JW, Duman RS. IL-1β is an essential mediator of the antineurogenic and anhedonic effects of stress. Proc Nat Acad Sci. 2008;105(2):751–6.
Article PubMed PubMed Central Google Scholar
Perera TD, Dwork AJ, Keegan KA, Thirumangalakudi L, Lipira CM, Joyce N, et al. Necessity of hippocampal neurogenesis for the therapeutic action of antidepressants in adult nonhuman primates. PLoS ONE. 2011;6(4): e17600.
Article PubMed PubMed Central Google Scholar
Kubera M, Obuchowicz E, Goehler L, Brzeszcz J, Maes M. In animal models, psychosocial stress-induced (neuro)inflammation, apoptosis and reduced neurogenesis are associated to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(3):744–59.
Daneman R, Prat A. The blood–brain barrier. Cold Spring Harb Perspect Biol. 2015;7(1): a020412.
Article PubMed PubMed Central Google Scholar
Larochelle C, Alvarez JI, Prat A. How do immune cells overcome the blood-brain barrier in multiple sclerosis? FEBS Lett. 2011;585(23):3770–80.
Comments (0)